DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION

Overview

INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is the #19 most commonly reported adverse reaction for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, manufactured by RB Health (US) LLC. There are 91 FDA adverse event reports linking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN to INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION. This represents approximately 1.0% of all 8,751 adverse event reports for this drug.

Patients taking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN who experience inappropriate schedule of product administration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is a less commonly reported adverse event for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, but still significant enough to appear in the safety profile.

Other Side Effects of DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN

In addition to inappropriate schedule of product administration, the following adverse reactions have been reported for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN:

• DRUG INEFFECTIVE — 1,293 reports
• OVERDOSE — 436 reports
• DIZZINESS — 397 reports
• DIARRHOEA — 364 reports
• ACCIDENTAL OVERDOSE — 333 reports
• COUGH — 254 reports
• NO ADVERSE EVENT — 238 reports
• NAUSEA — 234 reports
• SOMNOLENCE — 182 reports
• HEADACHE — 181 reports

Other Drugs Associated with INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION

The following drugs have also been linked to inappropriate schedule of product administration in FDA adverse event reports:

Does DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN cause INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION?

INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION has been reported as an adverse event in 91 FDA reports for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION with DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN?

INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION accounts for approximately 1.0% of all adverse event reports for DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, making it a notable side effect.

What should I do if I experience INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION while taking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN?

If you experience inappropriate schedule of product administration while taking DEXTROMETHORPHAN HYDROBROMIDE AND GUAIFENESIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages